Propranolol for Treatment of Cocaine Addiction - 2

This study has been completed.
Sponsor:
Collaborator:
University of Pennsylvania
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000197
First received: September 20, 1999
Last updated: February 3, 2010
Last verified: February 2010
  Purpose

The purpose of this study is to evaluate the safety and efficacy of propanolol in the early treatment of cocaine dependence.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Propranolol
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Propranolol for Treatment of Cocaine Addiction

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Side effects
  • Cocaine use
  • Cocaine withdrawal
  • Cocaine craving
  • Mood and anxiety
  • Clinical improvement

Estimated Enrollment: 0
Study Start Date: January 1987
Study Completion Date: January 2002
Primary Completion Date: January 2002 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   25 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000197

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: Kyle Kampman, M.D. University of Pennsylvania
  More Information

No publications provided

Responsible Party: Kyle Kampman, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00000197     History of Changes
Other Study ID Numbers: NIDA-00238-2, K20DA000238
Study First Received: September 20, 1999
Last Updated: February 3, 2010
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Propranolol
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Vasodilator Agents

ClinicalTrials.gov processed this record on April 17, 2014